Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110
Structure
Structure GPCR | 0.00 |
Citizens analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:
GPCR) with a Market Outperform and lowers the price target from $113 to $110.
